本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
TAIPEI, Feb. 5, 2026 /PRNewswire/ -- The Asian Smart Medical Online Exhibition 2026 (Medical Asia 2026) is a premier hybrid exhibition designed to seamlessly connect Asian medical suppliers, importers, and exporters with buyers from around the world. Taking place from February 3, 2026, to May 31, 2026, Medical Asia 2026, this four-month online exhibition provides exhibitors with an exceptional platform to showcase their brands, products, and innovations to a truly global audience. Organized by AsianNet and TradeAsia (www.e-tradeasia.com), Medical Asia has been successfully facilitating international medical trade since its launch in 2024 , earning a strong reputation for high-quality participation and tangible business outcomes. In 2026, Medical Asia extends its exhibition period to strategically align with major global healthcare and medical industry events, including Medical Design & Manufacturing West, Arab Health, HIMSS Global Health Conference & Exhibition, MEDICAL JAPAN [Osaka], and Hospitalar Sao Paulo. This extended timeline enables international buyers to engage with multiple key events simultaneously, creating a more efficient and streamlined sourcing experience. By participating in Medical Asia 2026, exhibitors can expect enhanced global exposure, broader networking opportunities, and increased potential for sustainable business growth, all while reaching a larger and more diverse international buyer base through a flexible and cost-effective hybrid exhibition model. Medical Asia 2026 features a robust lineup of respected Taiwanese manufacturers, including industry leaders such as Perfect Medical and many more. These companies will present thousands of the latest smart medical industry products and technologies, covering a wide array of sectors crucial to modern manufacturing and production. The event will feature an extensive selection from top manufacturers, covering categories such as Medical Devices & Clinical Equipment, Medical Supplies & Nursing Consumables, Healthcare Facility Furniture & Logistics Equipment, Emergency & Clinical Patient Monitoring Equipment, Rehabilitation & Physiotherapy Equipment / Consumables, Pharmaceutical Manufacturing, Packaging & Inspection Machinery, Medical-grade Wearables & Remote Patient Monitoring (RPM) Devices, Clinical Laboratory & IVD Analyzers, Medical-grade Materials & Components (Plastics / Rubber / Silicone, etc.), and Home Health Care Products. With thousands of the latest products, accessories, and equipment on display, the exhibition promises to be both comprehensive and highly professional. Attendees will gain valuable insights into the latest innovations and developments across the smart medical industry. Visit the Online Exhibition:https://www.etradeasia.com/online-show/42/Asian-Smart-Medical-Online-Exhibition-2026.html In today's rapidly evolving global environment, online platforms play a crucial role in breaking geographical barriers and extending marketing reach. In response to this growing demand, Medical Asia 2026 offers a comprehensive suite of innovative digital exhibition solutions, including dedicated exhibitor pages, electronic catalogs, and virtual exhibition halls. These digital tools are seamlessly integrated with TradeAsia, enabling international buyers worldwide to effortlessly discover exhibitors and explore products in depth. Through the platform, buyers can visit individual manufacturer pages, review detailed product information, submit inquiries, and communicate with exhibitors via real-time messaging. This highly interactive and user-friendly experience facilitates smooth communication, enhances buyer engagement, and fosters meaningful business connections between exhibitors and global buyers, ultimately creating valuable commercial opportunities. TradeAsia (www.e-tradeasia.com) has been providing comprehensive B2B international trade services for buyers and sellers worldwide since 1997. With nearly three decades of industry experience, TradeAsia is recognized as one of the most established and professional global trade platforms. Today, the platform serves millions of members worldwide, featuring more than 600,000 verified suppliers and millions of up-to-date product listings across diverse industries. Every day, thousands of professional buyers from around the world use TradeAsia to source products, connect with suppliers, and explore new business opportunities. As a leading trade promotion channel in Asia, TradeAsia continues to facilitate efficient cross border trade and foster long term partnerships between global buyers and suppliers. TradeAsia also collaborates with hundreds of trading organizations around the world to exchange marketing and promotional opportunities. As a result, suppliers who showcase their products on TradeAsia gain the chance to be featured across the publicity channels of multiple trade platforms and exhibition organizers worldwide, greatly enhancing their international visibility and marketing reach. In addition, during the period of Medical Asia 2026, promotional messages will be broadcast globally, further amplifying exposure for participating suppliers and connecting them with a wider international audience. Media Contact: Doreen ChenMarketing Manager, TradeAsiaEmail: service@etradeasia.com
SHANGHAI, Feb. 5, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into an exclusive license agreement with Shaanxi Micot Pharmaceutical Technology Co., Ltd. ("Micot") to commercialize MT1013, the world's first-in-class dual-targeting receptor agonist polypeptide that simultaneously targets the Calcium-Sensing Receptor (CaSR) and the Osteogenic Growth Peptide (OGP) receptor and is primarily developed with Secondary Hyperparathyroidism (SHPT) as its leading indication, in China and Asia-Pacific (excluding Japan). According to the agreement, Everest Medicines will pay Micot an upfront payment of RMB 200 million and potential regulatory and commercial milestone payments of up to RMB 1,040 million. MT1013 has entered Phase III clinical trial in China and the relevant development expenses will be covered by Micot. The strategic collaboration is expected to complement Everest Medicines' existing renal pipeline and drive operating synergies, further strengthen the Company's commercial product portfolio, and solidify its leading position in renal and autoimmune diseases in Asia, which are key therapeutic areas of focus. The collaboration will also expand the Company's nephrology portfolio from IgA nephropathy to a broader range of chronic kidney diseases (CKD). MT1013 is the world's first-in-class dual-targeting receptor agonist polypeptide internally developed by Micot. The Phase II data were presented orally and in a Late-Breaking session at the 2025 American Society of Nephrology (ASN) Annual Meeting. MT1013 uniquely combines the calcium-sensing receptor (CaSR) and the osteogenic growth peptide (OGP) receptor, addressing imbalances in parathyroid hormone (PTH), calcium, and phosphate metabolism. This innovative dual mechanism allows MT1013 to control SHPT and related bone metabolism disorders at the source, and to actively promote bone formation and repair through direct activation of osteogenic pathways, representing a therapeutic innovation shift from indirect inhibition of bone resorption to active stimulation of bone formation. Clinical studies have demonstrated that MT1013 acts rapidly, with strong and durable efficacy, and has a favorable safety profile in patients with CKD on maintenance hemodialysis with SHPT. It has shown potential advantages over current therapies in achieving comprehensive endpoints, including control of intact parathyroid hormone (iPTH), serum calcium, and phosphate levels, as well as improving calcium-phosphate balance and offering potential cardiovascular benefits. MT1013 is currently being evaluated in a Phase III clinical trial in China for this patient population, with over 50% of the target enrollment already achieved. SHPT is one of the most common and serious complications in patients with CKD. It causes disturbances in calcium and phosphate metabolism, elevated PTH levels, bone disorders, and vascular calcification, which substantially increase the risk of fractures, cardiovascular events, and mortality. SHPT is therefore an important factor influencing outcomes and prognosis in patients with CKD. With the global prevalence of CKD continuing to rise, the unmet medical need for effective SHPT therapies is also growing. Data indicate that the global population of patients with CKD has increased from 905.2 million in 2019 to 1.0655 billion in 2024 and is projected to exceed 1.2 billion by 2030 and 1.5 billion by 2035. Over the same period, the number of patients with SHPT has also continued to rise and is expected to reach approximately 189.9 million by 2030 and 221.7 million by 2035, highlighting a substantial and growing unmet medical need. "We are very pleased to collaborate with Micot. As the global burden of chronic kidney disease continues to rise, addressing patients' unmet needs remains a top priority.," said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. "MT1013 represents an innovative asset with the potential to expand treatment options for patients with secondary hyperparathyroidism. Through this partnership, we aim to leverage our expertise in autoimmune-related kidney disorders while broadening our renal portfolio to include additional diseases, including glomerulonephritis and complications associated with dialysis. Looking ahead, we will jointly advance the development and commercialization of MT1013 to bring innovative treatment options to a broader population of patients with kidney disease." "We are delighted to enter into this strategic collaboration with Everest Medicines. Everest's deep expertise in nephrology and established commercialization capabilities make it an ideal partner to bring MT1013 to patients in China and beyond," said Dr. Bing Wang, Founder, Chairman, and President of Micot. "MT1013 is a pivotal achievement of our peptide technology platform and a key milestone in our commitment to advancing innovative therapies for chronic diseases. Its unique dual-targeting mechanism has the potential to deliver meaningful advances in the treatment of secondary hyperparathyroidism. We look forward to working closely with Everest to accelerate clinical development and commercialization, address critical unmet medical needs, and advance care for patients with kidney disease." MT1013 has completed its pivotal Phase II clinical trial, which demonstrated robust and sustained iPTH suppression in patients with SHPT undergoing maintenance hemodialysis. In head-to-head comparisons with etelcalcetide, MT1013 showed advantages in comprehensive disease management, achieving higher rates of simultaneous control of iPTH, serum calcium, and phosphate, as well as greater reductions in phosphate and the cardiovascular risk marker FGF-23. Over 52 weeks of treatment, MT1013 also resulted in significant improvements in bone mineral density and bone metabolism markers, supporting the potential clinical benefits of its unique dual-target mechanism in both disease management and bone health. Building on these positive results, the Phase II data were presented orally and in a Late-Breaking session at the 2025 American Society of Nephrology Annual Meeting. MT1013 has now advanced into a confirmatory Phase III clinical trial in China with cinacalcet as the active comparator. The Phase III study has been launched across more than 100 sites nationwide, aiming to enroll approximately 424 patients, specifically targeting individuals with SHPT undergoing maintenance hemodialysis due to chronic kidney disease. About MT1013 MT1013 is the world's first-in-class dual-targeting receptor agonist polypeptide that simultaneously targets the Calcium-Sensing Receptor (CaSR) and the Osteogenic Growth Peptide (OGP) receptor and is primarily developed with Secondary Hyperparathyroidism as its leading indication and is planned to expand into additional indications including Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) with Osteoporosis and SHPT not on Dialysis. MT1013 completed its Phase II clinical trial (MT1013-II-C01) for the treatment of SHPT in May 2025 and has entered a Phase III clinical trial using Cinacalcet as the active comparator. About Everest Medicines Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies. The Company's therapeutic areas of focus include autoimmune, ophthalmology, critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company's website: www.everestmedicines.com. About Micot Shaanxi Micot Pharmaceutical TechnologyCo., Ltd.("Micot") was founded in Xi'an in January 2007 and now operates in China (Xi'an, Suzhou, Beijing, Shanghai, Hong Kong) and the U.S. An R&D-driven innovator, Micot develops dual- and multi-functional peptide drugs for cardiovascular/cerebrovascular and metabolic diseases to address unmet clinical needs. As the proposer, implementer, validator, and developer of the bispecific peptide concept, Micot stands as a premier platform for peptide drug R&D. It utilizes a unique mechanism for screening multi-target peptide therapeutics and possesses platform-based R&D capabilities to develop both First-in-class and Best-in-class candidates. Currently, Micot has a robust reserve of new drug candidates, with seven proprietary innovative pipelines currently in clinical stage: one in Phase III, three in Phase II, and three in Phase I. Dedicated to creating breakthrough medicines and saving lives, Micot strives to address unmet clinical needs and leverages scientific innovation to safeguard human health. For more information, please visit the website: www.micot.cn. Forward-Looking Statements This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.
DUBAI, UAE, Feb. 4, 2026 /PRNewswire/ -- Bybit, the world's second-largest cryptocurrency exchange by trading volume, announced another milestone for Mantle Vault on Bybit On-Chain Earn, an innovative yield-generating product launched in partnership with Mantle and Cian. Since January 8, 2026, Mantle Vault has added another US$50 million in assets under management (AUM) in just four weeks. Navigating complex conditions in a turbulent macroeconomic environment, Mantle Vault delivers consistent stablecoin on-chain yield through market-neutral strategies. Launched on December 22, 2025, Mantle Vault hit its first US$100 million in AUM in early January and has officially surpassed US$150 million in AUM today. A unique access point to DeFi yield anchored in smart stablecoin strategies, and readily available on Bybit's ultra user-friendly CeFi interface, Mantle Vault helps users put the search for return on auto pilot. As market conditions evolve and sharp corrections become the daily norm in recent months. Investors are increasingly turning to diversification solutions and expanding their access to broader markets. Mantle Vault, a structured DeFi product with reduced exposure to market volatility, sits at the forefront of DeCeFi convergence. "In today's markets, even risk-takers need a stable home to park their idle assets. Mantle Vault provides exactly that. Users don't have to compromise on yield and they get to distance themselves from high volatility. It is proof that DeFi can offer the kind of sophisticated, structured products traditionally reserved for institutional finance," said Jerry Li, Head of Financial Products and Wealth Management at Bybit. How It Works: Yield Generation: Users may earn returns through Ethena staking (sUSDe) and leveraged staking of USDT, USDC, and USDe on Aave V3 with potential additional incentives from Bybit and Mantle partnerships. Mechanism and Strategies: Mantle Vault deploys market-neutral strategies managed by Cian to minimize volatility exposure. Assets are secured by audited smart contracts on Aave V3 (Ethereum mainnet). The highly flexible product also offers zero subscription fees, and a low entry threshold starting at just 10 USDT or USDC, with most withdrawals processed within 0–3 days. Terms and conditions apply. Past APR does not guarantee future APR. Returns may change due to Aave market demand, Ethena rewards or gas cost fluctuations. For details on qualification rules, restrictions, and eligibility, users may visit: [Bybit x Mantle x Cian] Introducing Mantle Vault: Stablecoin on-chain yield strategy built for stability, flexibility, and scale #Bybit / #CryptoArk / #IMakeIt About Bybit Bybit is the world's second-largest cryptocurrency exchange by trading volume, serving a global community of over 80 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com. For more details about Bybit, please visit Bybit PressFor media inquiries, please contact: media@bybit.comFor updates, please follow: Bybit's Communities and Social Media Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube
ONTARIO, Calif., Feb. 4, 2026 /PRNewswire/ -- Nature's Miracle Holding Inc. (OTCQB: NMHI) ("Nature's Miracle" or the "Company"), a leader in controlled environment agricultural technology, today announced it has entered into a formal Settlement Agreement and Mutual Release with Megaphoton Inc. The agreement effectively resolves all outstanding legal disputes and trade payables between the two parties. Under the terms of the agreement, Nature's Miracle will issue 15 million shares of common stock (approximately 13% of the Company's outstanding shares) to Megaphoton at a valuation of $0.46 per share. This issuance serves as full consideration for the forgiveness of $6.9 million in trade payables previously owed by Nature's Miracle's subsidiaries, Visiontech Group and Hydroman Inc. Additionally, the Company has agreed to reimburse Megaphoton $300,000 for legal costs. This strategic settlement results in a one-time gain of $6.9 million and a corresponding increase in shareholder equity for the first quarter of 2026. The agreement brings a definitive end to the litigation process that began in 2022, when both companies filed complaints and cross-complaints against one another. "We want to express our gratitude to the Megaphoton team for working with us to resolve this long-standing legal uncertainty," said Tie 'James' Li, Chairman and CEO of Nature's Miracle. "This settlement significantly reduces our liabilities and rationalizes our balance sheet, setting the stage for the Company's future growth and uplifting. We look forward to relaunching our agriculture and indoor growing business with the potential for future cooperation with Megaphoton, a premier producer of indoor growing equipment." This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Nature's Miracle Holding Inc. Nature's Miracle (www.Nature-Miracle.com) is a growing agriculture technology company providing equipment and services to the Controlled Environment Agriculture ("CEA") industry, including vertical farming in North America. Through its two wholly-owned subsidiaries, Visiontech Group, Inc. and Hydroman, Inc., Nature's Miracle provides grow lights and hydroponic products to hundreds of indoor growers. The Company also maintains a robust pipeline to build commercial-scale greenhouses to meet the growing demand for fresh, local produce in North America. About Megaphoton Inc. Megaphoton (www.mphoton.com) operates at the forefront of the smart agriculture industry, providing advanced iGH fully controlled industrial greenhouse environmental systems. Their self-developed technologies include artificial light systems, water-fertilizer integration, and central management systems that regulate temperature, humidity, light, water, fertilizer, and gas. Megaphoton has successfully executed over 300 large-scale smart greenhouse projects across the Netherlands, Germany, the United States, Canada, and Australia. Forward-Looking Statements The information in this press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "forecast," "intends," "may," "will," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: the intended use of proceeds from the offering; successful launch and implementation of NMHI's joint projects with manufacturers and other supply chain participants of steel, rubber and other materials; changes in NMHI's strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; NMHI's ability to develop and launch new products and services; NMHI's ability to successfully and efficiently integrate future expansion plans and opportunities; NMHI's ability to grow its business in a cost-effective manner; NMHI's product development timeline and estimated research and development costs; the implementation, market acceptance and success of NMHI's business model; developments and projections relating to NMHI's competitors and industry; and NMHI's approach and goals with respect to technology. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the listing of the Company's shares on Nasdaq; changes in applicable laws or regulations; the effects of the COVID-19 pandemic on NMHI's business; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which NMHI operates; the risk that NMHI and its current and future collaborators are unable to successfully develop and commercialize NMHI's products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that NMHI is unable to secure or protect its intellectual property; the possibility that NMHI may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in NMHI's filings from time to time with the Securities and Exchange Commission.
ONTARIO, Calif., Feb. 4, 2026 /PRNewswire/ -- Nature's Miracle Holding Inc. (OTCQB: NMHI) today announced the appointment of Dr. Jinlong "Frank" Du as President of the Company's Agricultural Business. Dr. Du is a globally recognized entrepreneur and technology leader in indoor growing and controlled environment agriculture ("CEA"), with more than 20 years of experience in modern CEA and advanced facility agriculture. He is the founder and former Chief Executive Officer of Megaphoton, Inc., a technology company specializing in advanced horticultural lighting and integrated greenhouse systems. Dr. Du is widely regarded as an early pioneer and leading proponent of the fully controlled industrial greenhouse (iGH) model, which integrates climate control, energy optimization, lighting systems, and production management to enable scalable, high-efficiency agricultural operations. Over the past two decades, he has played a central role in the planning, design, and execution of large-scale industrial greenhouse projects, contributing across technology development, system integration, and commercial deployment. His expertise encompasses greenhouse infrastructure, advanced lighting technologies, energy-efficient systems, and high-yield crop production for commercial agriculture. Throughout his career, Dr. Du has successfully led and executed more than 300 large-scale smart greenhouse projects across the Netherlands, Germany, the United States, Canada, and Australia. Dr. Du holds a Ph.D. in Electronics and Electrical Engineering from Nanyang Technological University in Singapore. He is a member of both the International Society for Horticultural Science (ISHS) and IEEE. The global Controlled Environment Agriculture (CEA) market is estimated at approximately $90 billion in 2025 and is projected to exceed $200 billion by 2030, representing a compound annual growth rate (CAGR) of approximately 14–16%. Growth in the CEA market is being driven by increasing urbanization, heightened focus on food security, water conservation, and the rapid adoption of advanced technologies such as IoT, artificial intelligence, robotics, and automation, which enhance operational control, increase yields, and reduce long-term costs. Nature's Miracle Holding aims to become an integrated supplier of products and services to the global CEA market. Under Dr. Du's leadership, the Company plans to expand U.S. manufacturing of agricultural equipment, including indoor grow lights, agricultural drones, robotic machinery, and other related equipment, with a strategic focus on offering "Made in USA" solutions to customers across the industry. "I am personally very excited to join Nature's Miracle, a U.S.-based platform focused on advancing CEA technologies," said Dr. Du. "I am confident that we can build Nature's Miracle into a prominent integrator of CEA solutions and products in North America and beyond. My goal is to achieve approximately $50 million in agriculture-related revenue in 2026." Tie "James" Li, Chairman and Chief Executive Officer of Nature's Miracle Holding Inc., added, "On behalf of the Company, I extend my warmest welcome to Dr. Du. He brings a deep level of expertise in both the manufacturing and distribution of CEA products and technologies. We are thrilled to have Dr. Du lead our agricultural initiatives and drive meaningful growth for Nature's Miracle." This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Nature's Miracle Holding Inc. Nature's Miracle (www.Nature-Miracle.com) is a growing agriculture technology company providing equipment and services to the Controlled Environment Agriculture ("CEA") industry, including vertical farming in North America. Through its two wholly-owned subsidiaries, Visiontech Group, Inc. and Hydroman, Inc., Nature's Miracle provides grow lights and hydroponic products to hundreds of indoor growers. The Company also maintains a robust pipeline to build commercial-scale greenhouses to meet the growing demand for fresh, local produce in North America. Forward-Looking Statements The information in this press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "forecast," "intends," "may," "will," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: the intended use of proceeds from the offering; successful launch and implementation of NMHI's joint projects with manufacturers and other supply chain participants of steel, rubber and other materials; changes in NMHI's strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; NMHI's ability to develop and launch new products and services; NMHI's ability to successfully and efficiently integrate future expansion plans and opportunities; NMHI's ability to grow its business in a cost-effective manner; NMHI's product development timeline and estimated research and development costs; the implementation, market acceptance and success of NMHI's business model; developments and projections relating to NMHI's competitors and industry; and NMHI's approach and goals with respect to technology. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the listing of the Company's shares on Nasdaq; changes in applicable laws or regulations; the effects of the COVID-19 pandemic on NMHI's business; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which NMHI operates; the risk that NMHI and its current and future collaborators are unable to successfully develop and commercialize NMHI's products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that NMHI is unable to secure or protect its intellectual property; the possibility that NMHI may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in NMHI's filings from time to time with the Securities and Exchange Commission.
Widespread "YOLO Mode" risks in AI coding tools are creating significant supply chain and data breach exposure MOUNTAIN VIEW, Calif., Feb. 4, 2026 /PRNewswire/ -- UpGuard, a leader in cybersecurity and risk management, released new research highlighting a critical security vulnerability within developer workflows. UpGuard's analysis of more than 18,000 AI agent configuration files from public GitHub repositories identified a concerning pattern: one in five developers have granted AI code agents unrestricted access to perform high-risk actions without human oversight. In using AI to improve efficiency, developers are granting extensive permissions to download content from the web, and read, write, and delete files on their machines without requiring developer permission. This comes at the cost of essential security guardrails, exposing organizations to major supply chain and data security risks. "Security teams lack visibility into what AI agents are touching, exposing, or leaking when developers grant vibe coding tools broad access without oversight," said Greg Pollock, director of Research and Insights at UpGuard. "Despite the best intentions, developers are increasing the potential for security vulnerabilities and exploitation. This is how small workflow shortcuts can escalate into major supply chain and credential exposure problems." Key Findings: Widespread Potential for Damage: 1 in 5 developers granted AI agents the permission for unrestricted file deletion, allowing a small error or prompt injection attack to recursively wipe a project or system. Risk from Unchecked AI Development: Almost 20% of developers let the AI automatically save changes to the project's main code repository, skipping a necessary human review. This automated setup creates a serious security gap, as it allows an attacker to easily insert harmful or malicious code directly into the production system or open-source projects, which could lead to widespread security compromises. High-Risk Execution Permissions: A significant number of files granted permissions for arbitrary code execution, including 14.5% for Python and 14.4% for Node.js, effectively giving an attacker full control over the developer's environment through a successful prompt injection. MCP Typosquatting Threat: Analysis of the Model Context Protocol (MCP) ecosystem revealed extensive use of lookalike servers, creating ripe conditions for attackers to impersonate trusted technology brands. In the registries where users look for these AI tools, for every server provided by a verified technology vendor there were up to 15 lookalikes from untrusted sources. These risks highlight a critical governance gap, slowing down incident response and increasing the likelihood of credential and data exposure. To read UpGuard's recent research on vibe coding, visit the following: YOLO Mode: Hidden Risks in AI Coding Agents: https://hubs.li/Q041Cb0H0 Emerging Risks: Typosquatting in the MCP Ecosystem: https://hubs.li/Q041CCpq0 About UpGuard's Breach Risk UpGuard's Breach Risk solution is designed to turn hidden shortcuts such as misconfigurations or overly broad permissions to early threat signals like dark web chatter, into clear, actionable visibility. By providing deep insight into the AI-generated changes, access, and data flow, UpGuard's Breach Risk solution helps security teams enforce a strict governance framework. About UpGuard Founded in 2012, UpGuard is a leader in cybersecurity and risk management. The company's AI-powered platform for cyber risk posture management (CRPM), provides a centralized, actionable view of cyber risk across an organization's vendors, attack surface, and workforce. Trusted by thousands of companies, UpGuard's platform is designed to help security teams manage cyber risk with confidence and efficiency. To learn more, visit www.upguard.com.
A12 藝術空間
environment
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
